Designing safer glucocorticoid drugs

Dec 01, 2010

Glucocorticoid drugs are used widely to treat numerous conditions, including rheumatoid arthritis, allergic reactions, asthma, and some forms of cancer, and transplant recipients.

The beneficial effects of these drugs are their potent antiinflammatory and immunosuppressive properties. However, their long-term use is limited by severe side effects, including high blood levels of glucose, fatty liver, and type 2 .

A team of researchers, led by Carolyn Cummins, at the University of Toronto, Ontario, has now shown that the LXR-beta is required in mice for glucocorticoid drugs to elicit many of their negative side effects.

Importantly, although mice lacking LXR-beta did not develop high levels of blood glucose or fatty liver when administered a glucocorticoid drug, they did show all the signs of immunosuppression.

The authors therefore suggest that glucocorticoid drugs designed to selectively target the glucocorticoid receptor and not LXR-beta should be safer than those currently in clinical use.

Explore further: FDA warning: men's testosterone drugs overused (Update)

More information: View this article at: www.jci.org/articles/view/4168… dc4d064ab086bbab636a

Provided by Journal of Clinical Investigation

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Gallbladder cancer may be linked to estrogens

Aug 16, 2010

A very aggressive disease with a poor prognosis, gallbladder cancer may be connected to higher exposure to estrogens, according to a group of researchers at the University of Houston (UH).

Recommended for you

FDA warning: men's testosterone drugs overused (Update)

10 hours ago

The Food and Drug Administration is warning doctors against over-prescribing testosterone-boosting drugs for men, saying the popular treatments have not been established as safe or effective for common age-related ...

Early benefit assessment increases transparency for study data

14 hours ago

Four years have passed since the introduction of the German Act on the Reform of the Market for Medicinal Products (AMNOG). AMNOG was primarily aimed at containing the increasing drug expenditure of the statutory health insurance ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.